Pragati Shukla, MD
Neurology · Bryn Mawr, PANPI 1891722195
Payments from drug & device makers
Across 214 payments — averaging $17.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$792
- AbbVie$489
- Sunovion Pharmaceuticals Inc.$314
- AstraZeneca$303
- Supernus Pharmaceuticals, Inc.$271
- Lundbeck LLC$189
- plus $1K from 31 others
What the payments were for
- Speaking & faculty fees$271%
- Food & beverage$3,68397%
- Education$762%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 48 | $792 |
| AbbVie(2 entities) | 29 | $489 |
| Sunovion Pharmaceuticals Inc. | 23 | $314 |
| AstraZeneca(2 entities) | 14 | $303 |
| Supernus Pharmaceuticals, Inc. | 26 | $271 |
| Lundbeck LLC | 6 | $189 |
| Biogen | 8 | $183 |
| GE HealthCare | 6 | $135 |
| Genentech USA, Inc. | 5 | $121 |
| EMD Serono, Inc. | 6 | $98 |
| Amgen | 5 | $97 |
| Pfizer | 5 | $89 |
| Axsome Therapeutics, Inc. | 3 | $76 |
| Upsher-smith Laboratories LLC | 2 | $45 |
| Grifols USA, LLC | 2 | $42 |
| Teva Pharmaceuticals USA, Inc. | 3 | $39 |
| Impel Pharmaceuticals Inc. | 2 | $37 |
| Mallinckrodt Hospital Products Inc. | 1 | $37 |
| CSL Behring | 2 | $37 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $34 |
| UCB, Inc. | 1 | $28 |
| Acorda Therapeutics, Inc | 1 | $27 |
| Johnson & Johnson | 1 | $25 |
| Eisai Inc. | 1 | $25 |
| Lilly USA, LLC | 1 | $24 |
| Bristol Myers Squibb | 1 | $23 |
| Scilex Pharmaceuticals Inc. | 1 | $23 |
| Bausch Health US, LLC | 1 | $23 |
| Avion Pharmaceuticals | 1 | $22 |
| Portola Pharmaceuticals, LLC | 1 | $21 |
| Neurelis, Inc. | 1 | $21 |
| Argenx US, Inc. | 1 | $21 |
| Avanir Pharmaceuticals, Inc. | 1 | $18 |
| TG Therapeutics, Inc. | 1 | $18 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Amneal Pharmaceuticals LLC | 1 | $13 |
| Akcea Therapeutics, Inc. | 1 | $11 |
How this compares
$3,786 in reported general payments places this provider in the 60th percentile of 941 neurology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CopaxoneGlatiramer Acetate | 28 | $190,966 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 15 | $123,266 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 13 | $53,132 |
| Ajovy SyringeFremanezumab-Vfrm | 32 | $49,640 |
| Emgality PenGalcanezumab-Gnlm | 65 | $46,748 |
| Nurtec OdtRimegepant Sulfate | 27 | $40,744 |
| UbrelvyUbrogepant | 24 | $34,875 |
| RestasisCyclosporine | 38 | $28,744 |
| Dihydroergotamine Mesylate | 24 | $25,928 |
| Dalfampridine ErDalfampridine | 18 | $21,803 |
| Aimovig AutoinjectorErenumab-Aooe | 23 | $16,998 |
| Topiramate ErTopiramate | 17 | $10,427 |
| Verapamil SrVerapamil Hcl | 22 | $3,471 |
| Lidocaine | 24 | $3,396 |
| Cyclosporine | 11 | $3,093 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Copaxone | $39 | $190,96628 claims |
| AbbVieUbrelvy, Restasis | $489 | $63,61862 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $34 | $53,13213 claims |
| PfizerNurtec Odt | $89 | $40,74427 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $13 | $2,12420 claims |
| Upsher-smith Laboratories LLCTopiramate | $45 | $72743 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 941 neurology providers in Pennsylvania.
Other neurology in Bryn Mawr
- David WeismanAbington$9.3M
- Amit Bar-OrPhiladelphia$7.7M
- Thomas LeistPhiladelphia$5.8M
- Jan DrappatzPittsburgh$4M
- Lauren ElmanPhiladelphia$3.3M
- David IrwinPhiladelphia$2.5M
- Paula ClemensPittsburgh$2.1M
- Anoopum GuptaPittsburgh$2M
- Daniel KremensPhiladelphia$1.9M
- Frances JensenPhiladelphia$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.